Neutre
Johnson & Johnson proposes $5.5 billion settlement to resolve talc cancer lawsuits
Ce briefing n’est pas encore disponible dans cette langue — version anglaise affichée.
Johnson & Johnson has proposed a $5.5 billion settlement to resolve approximately 76,000 lawsuits alleging its talc products caused ovarian cancer. The settlement is contingent upon at least 95% of claimants participating. This move aims to conclude a decade-long legal battle and allows the company to focus on its core mission of developing life-saving medicines and devices.
Points clés
- Johnson & Johnson has agreed to pay $5.5 billion to settle remaining talc-related lawsuits, contingent on 95% claimant participation.
- The company plans to make an initial payment of up to $3 billion in 2027, with no further payments due until 2028.
- Johnson & Johnson believes it would have ultimately won in court but chose settlement to move forward.
- Shares of the company rose more than 2% before the market opened following the announcement.
Sources
- Johnson & Johnson proposes $5.5 billion talc settlement to end marathon legal fightAssociated Press · July 28, 2026
- Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuitThe Guardian · July 28, 2026
- Johnson & Johnson proposes $5.5 billion talc settlement to end marathon legal fightThe Washington Post · July 28, 2026
- Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuitReuters · July 28, 2026
Généré par IA à partir de sources d'actualités publiques. Ceci n'est pas un conseil financier.
